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Abstract
Purpose: We tested therapeutic efficacy of two dose paint-
ing strategies of applying higher radiation dose to tumor
subvolumes with high FDG uptake (biologic target volume,
BTV): dose escalation and dose redistribution. We also inves-
tigated whether tumor response was determined by the high-
est dose in BTV or the lowest dose in gross tumor volume
(GTV).
Experimental Design: FDG uptake was evaluated in rat rhab-
domyosarcomas prior to irradiation. BTV was defined as 30% of
GTV with the highest (BTVhot) or lowest (BTVcold) uptake. To test
efficacy of dose escalation, tumor response (time to reach two
times starting tumor volume, TGTV2) to Hot Boost irradiation
(40%higherdose toBTVhot)was comparedwithColdBoost (40%
higher dose to BTVcold), whilemean dose toGTV remained 12Gy.
To test efficacy of dose redistribution, TGTV2 after Hot Boost was
compared with uniform irradiation with the same mean dose
(8 or 12 Gy).
Results: TGTV2 after 12Gy delivered heterogeneously (Hot and
Cold Boost) or uniformly were not significantly different: 20.2,
19.5, and 20.6 days, respectively. Dose redistribution (Hot Boost)
with 8 Gy resulted in faster tumor regrowth as compared with
uniform irradiation (13.3 vs. 17.1 days; P ¼ 0.026). Further
increase in dose gradient to 60% led to a more pronounced
decrease in TGTV2 (10.9 days; P < 0.0001).
Conclusions: Dose escalation effect was independent of
FDG uptake in target tumor volume, while dose redistribution
was detrimental in this tumor model for dose levels applied
here. Our data are consistent with the hypothesis that tumor
response depends on the minimum intratumoral dose. Clin
Cancer Res; 21(24); 5511–8. 2015 AACR.
Introduction
Noninvasive functional or molecular imaging techniques
such as positron emission tomography (PET) allow detection
of spatial distribution of biologic phenotypes within a tumor,
which might serve as surrogates of radioresistance. It has been
hypothesized that radiation dose painting, that is, the prescrip-
tion of a nonuniform radiation dose distribution to the gross
tumor volume (GTV), based on the image-guided identification
of potentially radioresistant biologic target volumes (BTV)
within the GTV, may improve radiotherapy outcome (1–3).
Regions with high 18F-fluorodeoxyglucose (FDG) uptake
within the metabolically active tumor areas are attractive
targets for subvolume boosting, that is, while tumor subvo-
lumes with elevated FDG avidity are irradiated with higher
doses, reduced doses (redistribution approach) or standard
curative doses (dose escalation approach) are delivered to the
rest of the tumor volume with no or lower FDG uptake. The
biologic rationale for this approach is that FDG uptake is
heterogeneous within a tumor; it reflects tumor areas with
high cell density, which are highly metabolically active, and
may identify the regions of radioresistant tumor cells owing to
hypoxia or other mechanisms of radioresistance (4–8). The
hypothesis of a more radioresistant tumor phenotype within
high FDG uptake regions is also supported by the observation
that (i) FDG uptake before or early during treatment is an
independent prognostic factor for the outcome of (chemo-)
radiotherapy in various tumor entities (9–11); (ii) regions
of high FDG uptake remain stable during radiotherapy (12),
and (iii) the residual metabolically active regions and local
recurrences after radiotherapy remain or appear in the high
pretreatment FDG uptake areas within the irradiated target
volume (13–16).
These clinical data support the use of FDG PET imaging
in target definition for dose painting. Numerous clinical
studies in several cancers have demonstrated the feasibility
to selectively escalate the dose to the tumor regions with
increased FDG uptake (17–25). Yet, evidence for the thera-
peutic benefit of dose painting strategies from clinical trials is
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still lacking. In this preclinical study in rats bearing syngeneic
subcutaneous rhabdomyosarcoma tumors, we aimed to eval-
uate the therapeutic efficacy of two dose painting strategies to
boost tumor subvolumes with high FDG uptake: (i) targeted
dose escalation and (ii) dose redistribution. Our hypothesis
that FDG high uptake regions are more radioresistant in
rhabdomyosarcoma model is supported by preliminary obser-
vation demonstrating large overlap between high FDG uptake
regions and high uptake of HX4 hypoxia PET tracer (Supple-
mentary Fig. S1; refs. 26, 27), supporting accumulation of
FDG in radioresistant hypoxic tumor regions. The feasibility of
this novel radiation treatment approach in rats using state-of-
the-art clinical imaging and irradiation devices, including 3D
portal dosimetry, has been reported previously (28). To test
the effect of dose escalation on tumor growth, 40% higher
dose was delivered to tumor subvolumes with high FDG
uptake than to the rest of the tumor (Hot Boost). Tumor
response to this treatment was compared with the tumor
response to the control treatment, that is, the same 40%
increase in dose to nontarget tumor subvolumes with low
FDG uptake (Cold Boost). According to our hypothesis, boost-
ing FDG high uptake subvolumes should be more effective as
compared with boosting FDG low uptake subvolumes, assum-
ing that regions with high FDG uptake include the majority of
radioresistant tumor cells. To test the effect of dose redistri-
bution strategy, a 40% or a 60% higher dose was delivered to
tumor subvolumes with high FDG uptake, while the rest of the
tumor was irradiated with a lower dose. The effect of this
redistribution treatment on tumor regrowth was compared
with that of uniform irradiation that served as a control.
Importantly, mean dose to GTV in experimental and control
arms was kept the same. In this complex study, we tested
isotoxic approach that is also used in ongoing clinical trials
(NCT01024829, NCT01504815), where patients are random-
ized between dose escalation of the entire primary tumor or to
the high FDG uptake regions inside the primary tumor (20).
The preclinical model used in this study will be of great value
to test the numerous different dose painting approaches that
cannot be tested in the clinic.
Materials and Methods
Animals and tumor model
Animal studies were conducted in accordance with guide-
lines and approval of the Animal Ethical Committee of the
University of Maastricht (Maastricht, the Netherlands). The
experiments were performed using adult male WAG/Rij rats
(weight  250 g) and previously well-characterized syngeneic
rhabdomyosarcoma R1 tumor model (kindly provided by
W. Landuyt, Experimental Radiotherapy, Katholieke Univer-
siteit, Leuven, Belgium; refs. 29–33). For the experiments,
tumor pieces (ca. 1 mm3) were implanted subcutaneously
(s.c.) in the left flank of anesthetized animals. Tumor pieces
were used in the sequential series for at most 10 to 12 trans-
plantations; thereafter transplantation was restarted from the
stock of frozen cells.
Experimental design and tumor response evaluation
The study design is outlined in Supplementary Fig. S2. When
tumors reached an average volume of 8.1 cm3 [standard devi-
ation (SD), 2.6 cm3], rats were subjected to computed tomog-
raphy (CT) or PET/CT imaging. Rhabdomyosarcoma tumors at
this size have an average necrotic fraction of 16% (range, 5%–
35%; n ¼ 9; unpublished data), which is in the range of human
tumor xenografts (34). Several hours after PET/CT imaging, the
tumors were either left untreated or a mean single dose to the
GTV of 8 or 12 Gy was delivered as uniform or heterogeneous
irradiation. The two dose levels applied in this study have been
selected on the basis of the previous results, demonstrating
significant growth delay after uniform irradiation with these
doses (33, 35). In all dose groups with heterogeneous irradi-
ation, the BTV was defined to represent 30% of the GTV. The
radiation doses are specified in Table 1.
The dose escalation strategy was tested for the mean dose to
the GTV of 12 Gy. The following radiation treatments were
compared:
1) Hot Boost 40%: 40% higher dose to BTVhot [i.e., 30% of the
GTV with the highest standardized uptake value (SUV)] than
to the rest of the tumor (GTV-BTV).
2) Cold Boost 40%: 40%higher dose to BTVcold (i.e., 30%of the
GTV with the lowest SUV) than to the rest of the tumor
(control).
The dose redistribution strategy was tested for themean dose to
the GTV of 8 or 12 Gy, which was kept constant for all treatment
arms:
1) Hot Boost 40%.
2) Hot Boost 60%: 60%higher dose to BTVhot than to the rest of
the tumor (only for 8 Gy mean dose).
3) Uniform irradiation (control).
In addition, the groups of tumors were uniformly irradiated
with 4, 6, or 15 Gy to obtain dose–response relationships. The
response of tumors to various radiation treatments was evalu-
ated by a tumor growth delay assay. Tumors were measured
three times per week using a Vernier caliper, and volumes were
Translational Relevance
Clinical studies have demonstrated (i) that tumor relapse
after irradiation occurs preferentially in tumor areas with high
18F-fluorodeoxyglucose (FDG) uptake and (ii) the feasibility
to selectively escalate radiation dose to the potentially radio-
resistant tumor subvolumes (dose painting) with increased
FDG uptake without exceeding normal tissue tolerance. Yet,
evidence proving the therapeutic gain of dose painting strat-
egies from clinical trials is still lacking. Therefore, in this
preclinical study in rat rhabdomyosarcoma, we tested thera-
peutic efficacy of two dose painting strategies to boost tumor
subvolumes with high FDG uptake: (i) targeted dose escala-
tion and (ii) dose redistribution. Although dose escalation to
high FDGuptakewas not superior to the same dose increase in
low FDG uptake subvolumes, dose redistribution was even
detrimental. Our data are consistent with the hypothesis that
tumor response is dependent on the minimum intratumoral
dose. Our findingsmay provide important information for the
design of clinical trials.
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calculated as (a  b  c)  p/6, where a, b, and c are the
orthogonal dimensions corrected for the thickness of skin.
Animals were observed until the tumor volume exceeded 25
cm3, until death, or until the animal appeared to suffer. Tumor
response was quantified as the time required to reach two times
the starting tumor volume as determined on the day of PET/CT
scan (TGTV2).
PET/CT data acquisition, image segmentation, treatment
planning, and irradiation
PET/CT images were acquired using a clinical PET/CT scanner
(Biograph 40; Siemens Healthcare). Two hours prior to PET/CT
imaging, FDG [19.9 (2.8) MBq] was injected intravenously (i.v.)
while animals were sedated with a mixture of ketamine/xylazine
[100 and 10 mg/kg, respectively, intraperitoneal (i.p.)]. Several
minutes prior to scanning (20-minute duration), alignment was
performed for each anesthetized (ketamine/xylazine) animal
with the laser guides; cross-hairs and lines were drawn with
skin-ink on previously shaved body areas for subsequent accurate
repositioning of the rats for irradiation. The tumors were covered
with 1-cm thick super stuff bolus (Radiation Product Design,
Inc.).
PET/CT images were acquired with an axial field of view (FoV)
of 162 mm and a spatial resolution of 5.3-mm FWHM at the
center of the FoV. The PET data were corrected for photon
attenuation using the acquired CT images. Correction for scatter
(3D), random counts, dead time, and decay of injected radio-
nuclides was also applied. First, a topogram was acquired fol-
lowed by a whole-body CT scan using a 1-mm reconstructed slice
thickness and a pitch of 0.8. Finally, for PET imaging a 20-minute
emission scan in list mode in one bed position was acquired and
reconstructed as 45 minutes. FDG uptake was quantified by
maximal SUV (SUVmax) asmaximal FDGactivity inGTV corrected
for the decay, injected dose, and body weight.
CT images were directly imported into Eclipse treatment plan-
ning system (TPS; v11, Varian Medical Systems) for uniform
irradiation treatment planning. To plan heterogeneous dose
distribution irradiation, PET/CT images were first imported into
Imalytics 3.0 (Philips Technologies GmbH) for tumor segmen-
tation and BTV determination. The GTV was manually delineated
on CT scans. PET images were segmented to obtain BTVhot and
BTVcold within GTV (vide supra). Next, the GTV and BTV contours
were imported into the Eclipse TPS. Finally, the animal body and
spinal cord in the treatment field were segmented automatically,
whereas the abdominal region containing the gastrointestinal
tract was manually delineated. For uniform irradiation, Rapid
Arc VMAT treatment plans were created using a single full arc,
while for heterogeneous plans two full arcs were required for
optimal dose distribution. Dose calculations were performed
with the Eclipse AcurosXB 10.0 algorithm (Varian Medical Sys-
tems) using the smallest grid size of 0.1 cm. The dose constraints
for the target structures and organs at risk are summarized
in Table 1. Dose homogeneity for the GTV in the case of uniform
irradiation is defined in such a way that 99% of the volume needs
to receive 90% to 110% of the prescribed dose, while 90% to
115% (80%–115% for 60% dose gradient) of the prescribed
dose has to be delivered to the BTV (20).
Several hours after PET/CT scan, anesthetized (sodium pento-
barbital, 60 mg/kg, i.p.) animals were repositioned on the couch
of a TrueBeam STx High-Definition 120 Multileaf Collimator
linac (Varian Medical Systems). A cone beam CT (CBCT) scan
was then acquired with the on-board imager (100 kVp, 73.2mAs)
and matching of the CBCT to the planning CT scans was per-
formed prior to irradiation. Animals were anesthetized for ca. 15
minutes before irradiation (duration maximum 14 minutes)
could be performed. Some animals (3 of 51) had to be reposi-
tionedup to three timeswith the subsequentCBCT scan to achieve
acceptable repositioning. After treatment, the dose metrics to the
target structures were recalculated on the basis of CBCT images as
described previously (28).
Metabolic response assessment
FDG PET/CT imaging of tumors irradiated with amean dose of
12 Gy was performed 7 days after treatment as described above.
The pre- and posttreatment CT and PET scans were delineated and
segmented in Imalytics 3.0 (Philips Technologies GmbH). The
location and volumeof the FDGuptake areaswithin theGTVwere
quantified using the thresholds 10%, 20%, 30%, 40%, and 50%
of the GTV with the highest SUV on both pre- and posttreatment
PET scans. CT images and PET contours were then imported into
the SmartAdapt image registration application (v11, Varian Med-
ical Systems). For most of the animals (8 of 12), the difference
betweenpre- andposttreatment tumor volumewas less than20%.
The maximum observed difference between pre- and posttreat-
ment GTV was 41%. In SmartAdapt using an automatic rigid
registration algorithm based on mutual information from CT
scans, the CT images of the posttreatment scan were fused to the
images of the pretreatment CT scan. If the automatic registration
resulted in poormatching between the two scans, the imageswere
manually registered on the basis of the tumor contours and
anatomy of surrounding bony structures and soft tissue. Then,
the PET contours on the posttreatment scan were propagated to
the pretreatment scan and the Dice similarity coefficient (DSC)
was calculated as 2[(Vpre\Vpost)/(VpreþVpost)], where Vpre and
Vpost are the volumesof the FDG-based segmentations onpre- and
posttreatment PET scans.
Statistical analysis
GraphPad Prism software (version 5.00 for Windows, Graph-
Pad Software) was used to perform statistical analyses. Mean
values with SDs are reported. Mean values were compared using
the independent sample t test. P values were adjusted formultiple
comparisons using the Bonferroni correction when relevant.
Linear regression analysis was used to test the correlations
Table 1. Constraints for the target structures and organs at risk for uniform
irradiation, heterogeneous boost of hot or cold FDG subvolumes with 40% or








Mean GTV dose 12 (8) 12 (8) 8
Min GTV dose (D99%) 10.8 (7.2) — —
Max GTV dose 13.2 (8.8) — —
Mean BTV dose — 15 (10) 10.85
Min BTV dose (D99%) — 13.5 (9) 8.7
Max BTV dose — 17.25 (11.5) 12.5
Mean (GTV-BTV) dose — 10.7 (7.1) 6.8
Min (GTV-BTV) dose (D99%) — 9.6 (6.4) 5.44
GI V8Gy 5% 5% 5%
Max spinal cord dose 7 7 7
NOTE: All doses are reported in units of Gy.
Abbreviations: GI, gastrointestinal tract; D99%, 99% of the volume receives dose
D99%; V8Gy, the maximal fractional volume of the organ receiving dose 8 Gy.
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between various parameters. P values less or equal to 0.05 were
considered as statistically significant.
Results
The FDG uptake as quantified by SUVmax was similar
between the different experimental arms. The average
SUVmax was 4.33 (1.57; n ¼ 42). Across different experimental
groups, an average BTV of 29.6% (2.3) was obtained. Small
deviations from the desired BTV of 30% can be explained by
slight volumetric changes occurring during transfer of the target
structures between different software applications. Some exam-
ples of dose distributions for uniform irradiation, Hot Boost
and Cold Boost heterogeneous irradiation are shown in Fig. 1.
The planned doses (calculated on the basis of the CT image)
and delivered doses (calculated on the basis of the CBCT
image) to the target structures as well as dose volume histogram
(DVH) metrics for mean dose 8 Gy are summarized in Sup-
plementary Table S1. These data for 12 Gy have been reported
previously (28). Visual rigorous inspection has identified four
tumors for a new rigid registration to improve the match of CT
and CBCT images and to calculate the delivered dose. Overall,
in most of the cases (25 of 27) the discrepancy between
planned and delivered doses and DVH metrics was less than
3% for all target structures. In the remaining two cases, the


























Examples of treatment plans for uniform dose
distribution, Hot Boost and Cold Boost
heterogeneous irradiation. Amean dose of 12 Gy
was prescribed to the GTV (green contour and
shading) and 15 Gy to the BTV with the highest
(hot, red contour and shading) or lowest (cold,
blue contour and shading) FDG uptake.
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irradiation, indicating that the planned doses and dose homo-
geneity in both low- and high-dose regions could be accurately
achieved. Radiation toxicity was not observed in any of the
treatment groups, regardless of the radiation protocol.
Rhabdomyosarcoma tumor model demonstrated clear dose–
response relationships, that is, TGTV2 significantly increases with
increasing uniform radiation doses (Supplementary Fig. S3).
Increasing dose by 40% to BTVhot with the highest FDG uptake
did not have a greater effect on tumor growth than the same dose
increase to BTVcold with the lowest uptake after irradiation with
mean dose of 12 Gy (Fig. 2A), indicating that this dose-escalation
strategy based on FDGuptake did not result in therapeutic benefit
in a rat rhabdomyosarcoma tumor model. Efficacy of the dose
redistribution approach has been tested for two dose levels by
comparing the tumor response to Hot Boost irradiation with that
to uniform irradiation, while keeping the mean dose to the GTV
constant. Redistributing ameandose of 12Gy in away that BTVhot
received a 40% higher dose than the remaining tumor volume
(GTV-BTV) resulted in TGTV2 that was not significantly different
from TGTV2 after uniform irradiation: 20.2 (4.4) vs. 20.6 (4.4)
days (Fig. 2B). In contrast, redistributing a mean dose of 8 Gy in
the same way resulted in significantly faster tumor regrowth as
comparedwith uniform8-Gy irradiation [13.3 (2.9) vs. 17.1 (3.1)
days; P ¼ 0.026; Fig. 2B]. Further increase of the dose gradient
between BTV and (GTV-BTV) to 60% (Table 1) led to an even
more pronounceddecrease in TGTV2 [10.9 (2.1)days;P<0.0001),
that is, to a worsening of radiation response (Fig. 2B).
Metabolic response was assessed in tumors irradiated with a
mean dose of 12 Gy delivered uniformly or as a Hot Boost 7 days
after treatment. The overlap between residual and pretreatment
high FDG uptake subvolumes as quantified by DSC showed
pronounced variation (Fig. 3). In particular, the DSC for 30% of
the total tumor volume with the highest SUV uptake varied
between 0.37 and 0.73 for uniform irradiation and between
0.29 and 0.72 for the Hot Boost irradiation. As expected, DSC
increasedwith increasing thresholds from10% to 50%of theGTV
with the highest FDG uptake (Fig. 3). The average DSCs were not
significantly different between the radiation protocols for any of
the subvolumes segmented on the basis of various thresholds on
pre- and posttreatment FDG scans.
Discussion
This, to the knowledge of the authors, is the first study
assessing the effect of radiation dose painting on tumor growth
based on FDG uptake in rat tumors using two strategies of
nonuniform dose distribution: dose escalation and dose redis-
tribution. The technical feasibility to deliver nonuniform dose
distributions to tumors in rats using state-of-the-art clinical
imaging and irradiation devices has been reported previously
in detail (28). In this study, boosting tumor subvolumes with
high FDG uptake with a 40% higher radiation dose resulted in
the same growth inhibition as the same dose escalation to the
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Growth curves of untreated tumors and tumors irradiated uniformly or heterogeneously with a mean GTV dose of 12 or 8 Gy to test efficacy of (A) dose
escalation and (B) dose redistribution approaches. Tumor response to radiation treatments was quantified as the time required to reach two times the starting
tumor volume (TGTV2). Each symbol represents a mean value; error bar, SD.
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the mean dose 12 Gy in such a way that the tumor subvolumes
with high FDG uptake received a 40% higher dose than the rest
of the tumor volume did not result in therapeutic gain as
compared with uniform irradiation with the same mean dose
to the GTV. For the lower dose level of 8 Gy, the same dose
redistribution by 40% resulted in faster tumor growth, and
therefore worse radiation response, as compared with uniform
irradiation. This negative effect on tumor growth was further
enhanced if 60% higher dose was delivered to subvolumes with
high FDG uptake, while dose to the rest of the tumor was
further decreased maintaining the mean dose to the GTV at 8
Gy. Our findings in a rat rhabdomyosarcoma tumor model
using two dose levels do not support the radiation dose
boosting approach with nonuniform dose distributions based
on FDG uptake. More importantly, a dose redistribution
approach, that is, a decrease of dose to tumor subvolumes
with low FDG uptake, while boosting the high FDG uptake
subvolumes, may even be detrimental, if the former dose is
lower than a standard curative dose in a clinical situation. Our
data, therefore, support the hypothesis that tumor response
depends on the minimum intratumoral dose.
The lack of effect of dose escalation to the tumor subvolumes
with high FDGuptake on tumor growthwas not expected because
several clinical studies have shown that tumor relapse after
irradiation occurs preferentially in tumor areas with high FDG
uptake (13–15). Moreover, a number of correlative preclinical
and clinical studies have shown that tumor areas with high FDG
uptake are associated with decreased local tumor control and
thereby with increased radioresistance (8–11). This association,
however, was not confirmed in some clinical studies (36, 37).One
might anticipate that in the rat rhabdomyosarcoma tumors inves-
tigated in this study tumor cells with high FDG uptake are not
more radioresistant making dose-escalation strategy based on
FDG uptake ineffective in this tumor model. One of the explana-
tions for the differential radiosensitivity between low and high
FDG uptake tumor regions may be predominant FDG accumu-
lation in radioresistant hypoxic areas. Preclinical and clinical
studies comparing spatial distribution of FDG and hypoxia tra-
cers, however, reported diverse results showing complete and
partial overlap or even clear spatial discordance in uptake of two
tracers (1, 6–8, 23, 38, 39). The spatial correlation of FDG and a
hypoxia tracer has not been tested systematically in the rat
rhabdomyosarcoma model investigated here, but preliminary
observations do not exclude at least a partial overlap between
high FDG uptake regions and high uptake of HX4 hypoxia PET
tracer (Supplementary Fig. S1; refs. 26, 27), supporting accumu-
lation of FDG in hypoxic tumor regions. In addition, metabolic
response data in this study showed diverse patterns of correspon-
dence between post- and pretreatment metabolically active sub-
volumes from very poor to a large overlap. A time point 7 days
after irradiation with 12 Gy prior to tumor regrowth (Fig. 2) was
chosen for evaluation. The value ofDSCof pre- and posttreatment
high FDG-uptake subvolumes was independent of radiation
protocol, while it was hypothesized that their overlap would be
higher after uniform irradiation as compared with radiation Hot
Boost, owing to the higher cell kill by the higher dose in the BTV.
Taken together, the data suggest that regions of high FDG uptake
are not more radioresistant in rat rhabdomyosarcomas and may
not contribute to the tumor regrowth after irradiation. Because
tumor response improves with increasing uniform radiation
doses to the entire tumor (Supplementary Fig. S3), supporting
efficacy of dose escalation, the present data stresses the impor-
tance of the development of tools to accurately identify target
tumor volume for dose painting. Hypothetically, only patients in
whom tracer uptake identifies location of radioresistant cells and
of local recurrences, for examples, subvolumes with high density
of cancer stem cells (25, 40), may benefit from targeted dose
escalation. Because spatial discordance between FDG and a hyp-
oxia tracer uptake may exist, the combination of both tracers
might be a powerful tool to determine high-risk tumor subvo-
lumes (7).
In contrast to our findings, a preclinical study in human head
and neck squamous cell carcinoma xenografts of Schuetze and
colleagues (41) have shown that 40% increase of radiation dose
from 25 to 35 Gy had a greater effect on radiation response in
tumors with high pretherapeutic FDG uptake than in tumors
with low FDG uptake. This preclinical investigation, however,
cannot be directly compared with this study because uniform
irradiation was delivered to the tumors stratified by median
SUVmax to low or high FDG uptake tumors assuming that each
tumor represents a subvolume of a tumor in a single patient,
whereas in this study, the nonuniform dose distributions were
applied on the basis of intratumoral FDG uptake. Here, we used
lower radiation doses of 8 and 12 Gy that have been shown
previously to induce significant growth delay in rhabdomyo-
sarcoma tumor model when delivered uniformly (33, 35).
Moreover, TGTV2 increases with increasing uniform radiation
doses (Supplementary Fig. S3). Therefore, based on the tumor
response to uniform irradiation, it is expected that 4-Gy dose
increment, for example, in Hot Boost radiation group (mean
dose 12 Gy: 10.7 Gy in (GTV-BTV) vs. 15 Gy in BTV), would
result in increase of TGTV2 under the assumption that tumor
regrowth predominantly depends on tumor cells with high
FDG uptake, thereby supporting the choice of radiation doses
used in the present growth delay assay. Another important
difference is that in the study by Schuetze and colleagues, an
endpoint of local tumor control was evaluated as opposed to
TGTV2 in the present growth delay assay. Nevertheless, radia-
tion growth delay is a valid assay to obtain indications on the
effect of novel approaches tested here with further validation
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The DSC representing spatial overlap of the pre- and posttreatment
subvolumes ranging between 10% and 50% of GTV with the highest SUV
for uniform and Hot Boost irradiation with mean GTV dose 12 Gy. Data,
mean  SD.
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observations that (i) growth delay reflects radiation-induced
cell kill, and (ii) growth delay correlates with local tumor
control after irradiation (42).
Remarkably, we demonstrate in this study that a decrease of
radiation dose to the tumor subvolumes with low FDG uptake,
while increasing the dose to high FDGuptake subvolumes in dose
redistribution approach is detrimental for some dose levels. This
negative effect is more pronounced the greater the dose difference
between the low and high FDGuptake regions, for the samemean
radiation dose. The importance of the dose delivered to the low
uptake tumor regions (GTV-BTV) is also supported by a just
significant positive correlation between minimum (GTV-BTV)
dose D95% (Supplementary Table S1) and radiation response
after 8-Gy 40% dose gradient (R2 ¼ 0.56; P ¼ 0.05), that is,
higher minimum dose D95% results in a greater tumor growth
delay.Notably, this correlationwas insignificant for the BTV target
structure. Overall, based on these results, the dose to the low FDG
uptake subvolumes should not be lower than a standard curative
dose in order to avoid undertreating the patients.
Several other assumptions and limitations have tobediscussed.
First, BTV was defined to represent 30% of the entire tumor
volume with the highest FDG uptake, whereas in clinical studies
BTV is defined as a tumor subvolume with SUV values above a
certain threshold, for example, 50% SUVmax (20, 37, 43). How-
ever, a standard method for the determination of an optimal
threshold for clinical use has not been established yet. In clinical
studies, BTVs are determined in different tumors in different
patients who have different genetic backgrounds, whereas in this
preclinical study, we assumed that tumors with identical genetic
background and in the same host have a similar proportion of
radioresistant cells. This assumption is also supported by similar
FDG uptake across rhabdomyosarcoma tumors investigated here.
Moreover, the fractional BTV of 30% in this study corresponds
well with the average highly metabolic fractional volume in
clinical studies, including ongoing clinical trial (NCT01024829)
testing the same isotoxic dose painting approach in patients
(7, 20). Importantly, constant BTV allows to include appropriate
controls to maintain mean dose to the entire tumor on the same
level. Second, in this proof-of-principle study single dose regi-
mens, although at two dose levels were tested, which limits
translation of the results into the clinical situation. Third, as only
one tumor model was studied confirmatory investigations using
further tumor models are warranted.
In conclusion, tumor response to dose escalation was inde-
pendent of whether radiation dose was increased to tumor sub-
volumes with high or low FDG uptake using nonuniform radi-
ation protocols in rat rhabdomyosarcomas. This approach is
therefore not recommended for testing in clinical trials unless it
has been demonstrated that BTV areas are stable and are more
radioresistant. Decreasing radiation dose to tumor subvolumes
with low FDG uptake, while boosting high FDG uptake regions
using dose redistribution approachmay be detrimental. Our data
are consistent with the hypothesis that tumor response depends
on the minimum intratumoral dose.
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